
|Articles|March 15, 2019
Pharmacy Practice in Focus: Health Systems
- March 2019
- Volume 8
- Issue 2
Improving the Performance of Specialty Pharmacists in the Care of Patients With Pulmonary Arterial Hypertension
Advertisement
FACULTY:
James S. Kalus, PharmD, FASHP Director of Pharmacy Henry Ford Health System Detroit, Michigan
EDUCATIONAL OBJECTIVES:
At the completion of this activity, the participant will be able to:
- Analyze the unaddressed gaps of reversal agents for direct oral anticoagulants (DOACs) and the risk of bleeding complications
- Identify patients hwho are at high risk for major bleeding secondary to DOAC use
- Examine current and emerging DOAC reversal agents and their safety and efficacy
- Explore the role of the health-system pharmacist in ensuring optimal management of the patient with DOAC-associated bleeding and implementing standards of practice for reversal agents using clinical vignetttes.
TARGET AUDIENCE: Health-system pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: March 15, 2019
EXPIRATION DATE: March 15, 2020
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
over 7 years ago
Use AUC to Optimize Vancomycin Dosingover 7 years ago
Approach Respiratory Illnesses Rationallyover 7 years ago
Manage Acute Pain in Those Using Opioidsover 7 years ago
Documenting 340B Value Is Key to Successover 7 years ago
Panelists Discuss Challenges of Diagnosing HEover 7 years ago
News and Trends March 2019over 7 years ago
Perform an AOR to Comply With USPover 7 years ago
Enterprise Collaborations Help Meet Challengesover 7 years ago
Cancer Pain Treatment Remains a Challengeover 7 years ago
Here Is What to Know About Vaccines for SeniorsAdvertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
5





































































































